Abstract | BACKGROUND: METHODS: RESULTS: A total of 518 patients met the eligibility requirements. Of 120 patients with metastatic disease, 62 were randomly assigned to the standard-therapy group and 58 to the experimental-therapy group. There was no significant difference in five-year event-free survival between the treatment groups (P=0.81). Among the 398 patients with nonmetastatic disease, the mean (+/-SE) five-year event-free survival among the 198 patients in the experimental-therapy group was 69+/-3 percent, as compared with 54+/-4 percent among the 200 patients in the standard-therapy group (P=0.005). Overall survival was also significantly better among patients in the experimental-therapy group (72+/-3.4 percent vs. 61+/-3.6 percent in the standard-therapy group, P=0.01). CONCLUSIONS:
|
Authors | Holcombe E Grier, Mark D Krailo, Nancy J Tarbell, Michael P Link, Christopher J H Fryer, Douglas J Pritchard, Mark C Gebhardt, Paul S Dickman, Elizabeth J Perlman, Paul A Meyers, Sarah S Donaldson, Sheila Moore, Aaron R Rausen, Teresa J Vietti, James S Miser |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 348
Issue 8
Pg. 694-701
(Feb 20 2003)
ISSN: 1533-4406 [Electronic] United States |
PMID | 12594313
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright 2003 Massachusetts Medical Society |
Chemical References |
- Dactinomycin
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Ifosfamide
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Bone Neoplasms
(drug therapy, mortality, pathology)
- Child
- Cyclophosphamide
(administration & dosage)
- Dactinomycin
(administration & dosage)
- Disease Progression
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Drug Administration Schedule
- Etoposide
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Ifosfamide
(administration & dosage, adverse effects, therapeutic use)
- Male
- Neuroectodermal Tumors, Primitive
(drug therapy, mortality, secondary)
- Prognosis
- Sarcoma
(drug therapy, mortality, secondary)
- Sarcoma, Ewing
(drug therapy, mortality, secondary)
- Survival Rate
- Treatment Failure
- Vincristine
(administration & dosage)
|